Neuregulin-1 transgenic mouse and methods of use

Details Neuregulin-1 transgenic mouse and methods of use Neuregulin-1 transgenic mouse and methods of use

2002-03-26

2009-02-24

Crouch, Deborah (Department: 1632)

Multicellular living organisms and unmodified parts thereof and

Method of using a transgenic nonhuman animal in an in vivo...

C800S009000, C800S018000

Reexamination Certificate

active

07495147

ABSTRACT:
Nucleic acids comprising the neuregulin 1 gene (NRG1) and encoding NRG1 polypeptides are disclosed. Also described are related nucleic acids encoding NRG1 polypeptides; NRG1 polypeptides; antibodies that bind to NRG1 polypeptides; methods of diagnosis of susceptibility to schizophrenia; assays for agents that alter the activity of NRG1 polypeptide or which identify NRG1 binding agents, and the gents or binding agents identified by the assays; NRG1 therapeutic agents, including the NRG1 nucleic acids, NRG1 polypeptides, or agents that alter the activity of an NRG1 polypeptides; pharmaceutical compositions comprising the NRG1 therapeutic agents; as well as methods of therapy of schizophrenia. Novel haplotypes with a common core haplotype in affected individuals are described, as well as their use in methods for screening for susceptibility to schizophrenia. Also described are hypomorphic mice for use in identifying phenotypes associated with schizophrenia, as well as for use in assessing agents of interest for neuroleptic activity and for potential therapeutic use for treatment of schizophrenia.

REFERENCES:
patent: 6218595 (2001-04-01), Giros et al.
patent: 6387638 (2002-05-01), Ballinger et al.
patent: WO 94/26298 (1994-11-01), None
patent: WO 98/42362 (1998-10-01), None
patent: WO 99/62955 (1999-12-01), None
patent: WO 01/64876 (2001-09-01), None
patent: WO 01/64877 (2001-09-01), None
Gerlai R. Gene targeting studies of mammalian behavior: is it the mutation or the background genotype? (1996) 19: 177-181.
Lariviere WR. Transgenic studies of pain and analgesia: Mutation or background genotype? (2001) 297: 467-473.
Petryshen TL, Support for involvment for neuregulin 1 in schizophrenia pathophysiology, 2005, Mol. Psychiatry, vol. 10, pp. 366-374.
Stefannson H, Neuregulin 1 and susceptibility to schizophrenia, 2002, Am. J. Hum. Genet., vol. 71, pp. 877-892.
Sandrock et al. Maintenance of Acetylcholine Receptor Number by Neuregulins at the Neuromuscular Junction in Vivo, 1995, Science, vol. 276, pp. 599-603.
Crawley JN, Behavioral phenotyping of transgenicand knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests, 1999, Brain Research, vol. 835, pp. 18-26.
1997, Montkowski et al., Brain Res., vol. 762, pp. 12-18.
1998, Picciotto et al., Physiological Rev., vol. 78, pp. 1131-1163.
1999, Crabbe et al., Science, vol. 284, pp. 1670-1672.
2004, Zimmer et al., Psychopharmacology, vol. 176, pp. 343-352.
Britsch, S., et al. “The ErbB2 and ErbB3 Receptors and their Ligand, Neuregulin-1, are Essential for Development of the Sympathetic Nervous System,”Genes&Development, 12:1825-1836 (1998).
Crovello, C.S., et al., “Differential Signaling by the Epidermal Growth Factor-Like Growth Factors Neuregulin-1 and Neuregulin-2,”Journal of Biological Chemistry, 273:26954-26961 (1998).
Elenius, K., et al., “A Novel Juxtamembrane Domain Isoform of HER4/ErbB4,”Journal of Biological Chemistry, 272:26761-26768 (1997).
Fitzpatrick, V.D., et al., “Formation of a High Affinity Heregulin Binding Site Using the Soluble Extracellular Domains of ErbB2 with ErbB3 or ErbB4,”FEBS Letters, 431:102-106 (1998).
Higashiyama, S., et al, “A Novel Brain-Derived Member of the Epidermal Growth Factor Family that Interacts with ErbB3 and ErbB4,”Journal of Biological Chemistry, 122:675-680 (1997).
Le, X.F., et al., “Anti-HER2 Antibody and Heregulin Suppress Growth of HER2-Overexpressing Human Breast Cancer Cells Through Difference Mechanisms,”Clinical Cancer Research, 6:260-270 (2000).
Rosen, M., “Downregulation and Increased Turnover of β-Amyloid Precursor Protein in Skeletal Muscle Cultures by Neuregulin-1,”Experimental Neurology, 181:170-180 (2003).
Stefansson, H., et al., “Association of Neuregulin 1 with Schizophrenia Confirmed in a Scottish Population,”Am. J. Human Genet., 72:83-87 (2003).
Straub, et al., “Genome-Wide Scans of Three Independent Sets of 90 Irish Multiplex Schizophrenia Families and Follow-Up Selected Regions in All Families Provides Evidence for Multiple Susceptibility Genes,”Molecular Psychiatry, 7:542-559 (2002).
Tang, C.K, et al., “Ribozyme-Mediated Down-Regulation of ErbB-4 in Estrogen Receptor-Positive Breast Cancer Cells Inhibits Proliferation Both in Vitro and in Vivo,”Cancer Research, 59:5315-5322 (1999).
Williams, N.M., et al., “Support for Genetic Variation in Neuregulin 1 and Susceptibility to Schizophrenia,”Molecular Psychiatry, 8:485-487 (2003).
Yang, J.Z., et al., “Association Study of Neuregulin 1 Gene with Schizophrenia,”Molecular Psychiatry, 8:706-709 (2003).
Yoo, J-Y, et al., “Interaction of the PA2G4 (EPB1) Protein with ErbB-3 and Regulation of this Binding by Heregulin,”British Journal of Cancer, 82:683-690 (2000).
Zhao, J.J. and Lemke, G., “Selective Disruption of Neuregulin-1 Function in Vertebrate Embryos Using Ribozyme-tRNA Transgenes,”Development, 125:1899-1907 (1998).
Mohn, A.R., et al., “Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia,”Cell, 98: 427-436 (1999).
Rieff, H.I, et al., “Neuregulin Induces GABAAReceptor Subunit Expression and Neurite Outgrowth in Cerebellar Granule Cells,”J. Neurosci. 19: 10757-10766 (1999).
Martin, P., et al., “Rodent Data and General Hypothesis: Antipsychotic Action Exerted Through 5-HT2A Receptor Antagonism is Dependent on Increased Serotonergic Tone,”J. Neural Transm.. 105: 365-396 (1998).
Swerdlow, N.R. and Geyer, M.A., “Using an Animal Model of Deficient Sensorimotor Gating to Study the Pathophysiology and New Treatments of Schizophrenia,”Schizophrenia Bulletin, 24: 285-301 (1998).
Dulawa, S.C. and Geyer, M.A., “Psychopharmacology of Prepulse Inhibition in Mice,”Chin. J. Physiol., 39: 139-146 (1996).
Harrison, P.J., et al., “Schizophrenia Genes, Gene Expression, and Neurophathology: On the Matter of Their Convergence,”Molecular Psychiatry10: 40-68 (2005).
Talmage, D.A. and L.W. Role, “Multiple Personalities of Neuregulin Gene Family Members,”Journal of Comparative Neurology, 472: 134-139 (2004).
Harrison, P.J. and Weinberger, D.R., “Schizophrenia Genes, Gene Expression, and Neuropathology: On the Matter of Their Convergence,”Molecular Psychiatry, 10: 40-68 (2005).
Jeschke, M., et al., “Targeted Inhibition of Tumor-Cell Growth by Recombinant Heregulin-Toxin Fusion Proteins,”International Journal of Cancer, 60:730-739 (1995).
Tang, C.K., et al., “ErbB-4 Ribozymes Abolish Neuregulin-Induced Mitogenesis,”Cancer Research, 58:3415-3422 (1998).
Azemar, M., et al., “Recombinant Antibody Toxins Specific for ErbB2 and EGF Receptor Inhibit the In Vitro Grown of Human Head and Neck Cancers and Cause Rapid Tumor Regression In Vivo,”International Journal of Cancer, 86:269-275 (2000).
Buonanno, A., et al., “Neuregulin and ErbB Receptor Signaling Pathways in the Nervous System,”Curr. Opinion in Neurobiology, 11:287-296 (2001).

Affiliated with

Also associated with

Rating

Neuregulin-1 transgenic mouse and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Neuregulin-1 transgenic mouse and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neuregulin-1 transgenic mouse and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4139040